

Annika Auranen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7026754/publications.pdf>

Version: 2024-02-01

15
papers

248
citations

1040056

9
h-index

1199594

12
g-index

17
all docs

17
docs citations

17
times ranked

409
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved survival after implementation of ultra-radical surgery in advanced epithelial ovarian cancer: Results from a tertiary referral center. <i>Gynecologic Oncology</i> , 2022, 165, 478-485.	1.4	3
2	Treatment patterns and time to next treatment among patients with OC in a real-life setting in Finland: The OCRWE-Finland study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18806-e18806.	1.6	0
3	Maximal surgical effort increases the risk of postoperative complications in the treatment of advanced ovarian cancer. <i>European Journal of Surgical Oncology</i> , 2022, 48, 2525-2530.	1.0	4
4	The Management of Peutz-Jeghers Syndrome: European Hereditary Tumour Group (EHTG) Guideline. <i>Journal of Clinical Medicine</i> , 2021, 10, 473.	2.4	65
5	Decreasing trend and changing indications of hysterectomy in Finland. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2021, 100, 1722-1729.	2.8	14
6	Cancer screening – Why do we still debate about the benefits?. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2020, 99, 443-444.	2.8	0
7	Expression of the miR-200 family in tumor tissue, plasma and urine of epithelial ovarian cancer patients in comparison to benign counterparts. <i>BMC Research Notes</i> , 2020, 13, 311.	1.4	21
8	Behavior of FDG-avid supradiaphragmatic lymph nodes in PET/CT throughout primary therapy in advanced serous epithelial ovarian cancer: a prospective study. <i>Cancer Imaging</i> , 2019, 19, 27.	2.8	10
9	Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma. <i>Gynecologic Oncology</i> , 2018, 149, 173-180.	1.4	16
10	Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). <i>British Journal of Cancer</i> , 2017, 116, 455-463.	6.4	33
11	Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer. <i>Tumor Biology</i> , 2017, 39, 101042831769118.	1.8	13
12	Postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer: The ENGOT-EN2/DGCG trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5613-TPS5613.	1.6	4
13	Palbociclib versus placebo in combination with letrozole for patients with advanced or recurrent endometrial cancer: The NSGO ENGOT-EN3/PALEO trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5612-TPS5612.	1.6	0
14	A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources. <i>Clinical Chemistry</i> , 2016, 62, 1390-1400.	3.2	21
15	18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 140, 29-35.	1.4	44